Azad A K M, Fatima Shadma, Capraro Alexander, Waters Shafagh A, Vafaee Fatemeh
School of Biotechnology and Biomolecular Sciences, University of New South Wales (UNSW Sydney), Sydney, NSW 2052, Australia.
Department of Medical Oncology, Ingham Institute of Applied Research, Sydney, Australia.
Patterns (N Y). 2021 Sep 10;2(9):100325. doi: 10.1016/j.patter.2021.100325. Epub 2021 Jul 14.
An effective monotherapy to target the complex and multifactorial pathology of SARS-CoV-2 infection poses a challenge to drug repositioning, which can be improved by combination therapy. We developed an online network pharmacology-based drug repositioning platform, COVID-CDR (http://vafaeelab.com/COVID19repositioning.html), that enables a visual and quantitative investigation of the interplay between the primary drug targets and the SARS-CoV-2-host interactome in the human protein-protein interaction network. COVID-CDR prioritizes drug combinations with potential to act synergistically through different, yet potentially complementary, pathways. It provides the options for understanding multi-evidence drug-pair similarity scores along with several other relevant information on individual drugs or drug pairs. Overall, COVID-CDR is a first-of-its-kind online platform that provides a systematic approach for pre-clinical investigation of combination therapies for treating COVID-19 at the fingertips of the clinicians and researchers.
针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染复杂且多因素的病理状况开发一种有效的单一疗法，对药物重新定位构成了挑战，联合疗法可能会改善这一状况。我们开发了一个基于网络药理学的在线药物重新定位平台COVID-CDR（http://vafaeelab.com/COVID19repositioning.html），该平台能够在人类蛋白质-蛋白质相互作用网络中对主要药物靶点与SARS-CoV-2-宿主相互作用组之间的相互作用进行可视化和定量研究。COVID-CDR对有可能通过不同但可能互补的途径发挥协同作用的药物组合进行优先级排序。它提供了理解多证据药物对相似性评分的选项以及关于单个药物或药物对的其他一些相关信息。总体而言，COVID-CDR是首个此类在线平台，为临床医生和研究人员提供了一种系统方法，用于在临床前研究治疗2019冠状病毒病的联合疗法。
